A hazard ratio of 0.40 in second-line metastatic pancreatic cancer is not a modest improvement — it represents a halving of the risk of death against cytotoxic chemotherapy, a control arm that has barely moved in decades. Revolution Medicines’ RASolute 302 trial of daraxonrasib produced a median overall survival of 13.2 months versus 6.7 months for chemotherapy, a magnitude of benefit that reframes what RAS(ON) inhibition can actually deliver in one of oncology’s most resistant tumor types.
The trial design matters as much as the numbers. RASolute 302 ran in an all-comers second-line PDAC population — not a biomarker-selected subset engineered to maximize effect size — which means the OS data reflects the realistic clinical universe of patients who progress on gemcitabine-based first-line therapy. That the PFS and OS results are both declared final, without interim cutoffs or immature data caveats, removes the usual statistical asterisks that accompany pancreatic cancer readouts. The planned NDA submission under the Commissioner’s National Priority Voucher program adds a regulatory timeline accelerant that could bring a decision faster than the standard pathway, particularly given the pre-existing Breakthrough Therapy Designation.
Revolution is also not treating this as a single-asset story. Three additional registrational Phase 3 studies in PDAC are either enrolling or initiating — covering adjuvant resectable disease, first-line metastatic monotherapy and combination settings, and a RAS(ON) inhibitor doublet pairing daraxonrasib with zoldonrasib. The Phase 3 NSCLC program in RAS G12D is fully enrolled in its Phase 2 expansion cohort, with a registrational trial imminent. The $2.2 billion raised in gross proceeds this year is not incidental context; it converts what could have been a one-shot pivotal bet into a platform capable of running six or more concurrent registrational trials without existential financing pressure.
The single marker worth tracking now is the ASCO Plenary presentation, where the full RASolute 302 dataset — subgroup analyses, depth of response, duration curves — will be scrutinized by the oncology community for any population-level heterogeneity that could complicate the label negotiation with FDA. A clean, consistent treatment effect across KRAS mutation subtypes would validate the multi-selective mechanism; any subgroup attenuation would sharpen the debate about whether G12D-selective zoldonrasib deserves priority over daraxonrasib in the broader PDAC program.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
